WORLD HEALTH ORGANIZATION

Ondine Biomedical launches phase three trial after FDA acceptance of its IND amendment. The trial, in collaboration with HCA Healthcare, involves 5,000 surgical patients and compares current infection prevention practices with and without its nasal photodisinfection technology. Recruitment is underway, with final patient enrolment expected by mid-2025. Early trial results anticipated in autumn 2025.

FDA grants orphan-drug designation to Jaguar Health's crofelemer for cholera diarrhea treatment, offering development incentives and 7-year market exclusivity upon approval.

The smart pills market was valued at USD 1.5 billion in 2023 and is projected to reach USD 4.9 billion by 2032, growing at a CAGR of 14.0%. Technological innovation and healthcare needs drive growth, with non-invasive methods gaining prominence. Regulatory approvals and clinical trials support market expansion, while smart pills offer potential healthcare cost savings of up to 20% globally by 2030.

The AI in precision medicine market is expected to grow from USD 0.78 billion in 2024 to USD 3.92 billion by 2030, driven by personalized treatments, advanced genomics, and drug development acceleration. AI analyzes complex data for quicker disease identification and tailored therapies, optimizing diagnostics and treatment outcomes. Key players include NVIDIA, Google, Microsoft, and IBM, focusing on innovations like deep learning and AI platforms for drug discovery.

EVA Pharma's insulin glargine injection, produced in collaboration with Eli Lilly, received approval from the Egyptian Drug Authority. This marks the first regulatory approval for EVA Pharma's insulin drug products, aiming to provide affordable insulin to one million people in low- to middle-income countries annually by 2030.

The RH5.1/Matrix-M malaria vaccine, studied in a Phase IIb trial, shows 55% efficacy against clinical malaria and over 80% against severe disease, with favorable safety and tolerability. It could complement existing pre-erythrocytic vaccines, offering a second line of defense against malaria.

The global personalized medicine biomarkers market is projected to grow from USD 21.85 billion in 2024 to USD 78.27 billion by 2034, at a CAGR of 13.6%. Biomarkers aid in early disease detection, prognosis, and treatment selection, driving market growth. Key drivers include advancements in genomics, growing prevalence of diseases like cancer, and partnerships between pharmaceutical and diagnostic firms. North America leads the market, while Asia Pacific is expected to grow fastest due to expanding healthcare infrastructure and rising demand for precision medicine.

Mayo Clinic's phase 2 study shows promising results with short-course hypofractionated proton beam therapy for older patients with glioblastoma, improving median overall survival to 13.1 months and quality of life.

References on tuberculosis research, including WHO reports, new TB vaccines, drug resistance, and treatment regimens.

King Charles reduces red meat in his diet to aid cancer battle. Research indicates plant-based foods improve cancer prognosis, while red meat may increase cancer risk. A balanced diet rich in fruits, vegetables, and whole grains is recommended for cancer prevention and survivorship.